September 30, 2020 – The Star
Narrow focus on vaccines is a risk we can’t afford
September 22, 2020 – The McGill Tribune
Canadian Biotech start-up to begin Phase 3 COVID-19 oral treatment trials
September 11, 2020 – Radio-Canada
La course au financement de remèdes contre la COVID-19 tiraille des scientifiques
September 7, 2020 – Global News
Developing coronavirus treatments ‘extremely important,’ experts say
September 3, 2020 – Radio-Canada
Un médicament contre la COVID-19 en cours d’élaboration à Dieppe
September 3, 2020 – TVA Nouvelles
Un autre médicament contre la COVID-19 testé au Québec
September 3, 2020 – La Presse
Un médicament générique contre la COVID-19 testé à Montréal
September 3, 2020 – Radio-Canada
Interview with Dr Jean Bourbeau (in French)
September 3, 2020 – Journal de Montréal
Un autre médicament contre la COVID-19 testé au Québec
September 3, 2020 – Complex
Canadian Drug Approved for Trials as COVID-19 Treatment Could Be Available This Year
September 3, 2020 – Narcity
A Canadian COVID-19 Treatment Just Got Phase 3 Trial Approval From The Government (VIDEO)
September 3, 2020 – Medical News
Reformulated generic drug could offer a cost-effective way to accelerate recovery, prevent hospitalizations
September 2, 2020 – 98.5 Montreal
Dr Jean Bourbeau radio interview on 98.5 Montreal with Paul Arcand (in French)
September 2, 2020 – News release
Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19
September 2, 2020 – News release
New COVID-19 Drug Therapy Developed by Canadian Biotech Start-up Headed for Phase III Clinical Trial Sponsored by the RI-MUHC
Looking to Invest?
Interested in investing or participating in the Clinical Trial?
Please complete the form below or email us at info@pulmonem.ca.
Pulmonem Inc.
855, Dieppe Blvd
Dieppe, NB E1A 7R8
CANADA
Media Enquiries
Keelan Green
613-220-2016
green@prospectus.ca